Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0SY9B
|
|||
| Former ID |
DCL001001
|
|||
| Drug Name |
SSR149415
|
|||
| Synonyms |
Nelivaptan; SSR 149415; 439687-69-1; UNII-3TY57MQ4OA; SR-149415; SSR-149415; 3TY57MQ4OA; CHEMBL582857; Nelivaptan [INN]; DSSTox_CID_27358; DSSTox_RID_82294; DSSTox_GSID_47358; GTPL2202; DTXSID7047358; SCHEMBL14517029; MolPort-042-665-640; Tox21_300240; BDBM50299343; ZINC42833251; DB12643; SSR-149,415; NCGC00254222-01; NCGC00247960-01; CAS-439687-69-1; (2S,4R)-1-[(3R)-5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-methoxyphenyl)-2-oxoindol-3-yl]-4-hydroxy-N,N-dimethylpyrrolidine-2-carboxamide; Nelivaptan; 1-(5-chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl)-4-hydroxy-N,N-dimethyl-2-pyrrolidinecarboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Anxiety disorder [ICD-11: 6B00-6B0Z] | Phase 2 | [1], [2], [3] | |
| Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2] | Phase 2 | [1], [2], [3] | ||
| Company |
Sanofi-Aventis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C30H32ClN3O8S
|
|||
| Canonical SMILES |
CN(C)C(=O)C1CC(CN1C2(C3=C(C=CC(=C3)Cl)N(C2=O)S(=O)(=O)C4=C(C=C(C=C4)OC)OC)C5=CC=CC=C5OC)O
|
|||
| InChI |
1S/C30H32ClN3O8S/c1-32(2)28(36)24-15-19(35)17-33(24)30(21-8-6-7-9-25(21)41-4)22-14-18(31)10-12-23(22)34(29(30)37)43(38,39)27-13-11-20(40-3)16-26(27)42-5/h6-14,16,19,24,35H,15,17H2,1-5H3/t19-,24+,30+/m1/s1
|
|||
| InChIKey |
NJXZWIIMWNEOGJ-WEWKHQNJSA-N
|
|||
| CAS Number |
CAS 439687-69-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2202). | |||
| REF 2 | Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for t... Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6370-5. | |||
| REF 3 | Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. | |||
| REF 4 | Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.